Biochemistry to Bedside Series - ACS Axial | ACS Publications

Biochemistry to Bedside Series

Introduced in 2018, the “Biochemistry to Bedside” series aims to track successes in drug development back to their biological and chemical roots.

In the Editorial Introducing Biochemistry to Bedside, Derek Lowe explained the sometimes winding path that a drug may take in moving from the bench to the clinic. Critical analyses of successes in drug discovery, combined with a deeper understanding of the biochemistry of health and disease, can facilitate new advances in human health.

Since 2018, a range of Viewpoints and Perspectives have been published in this series, examining the development of drugs and therapies to treat a range of conditions and diseases.

Explore articles from the Biochemistry to Bedside Series:

Introducing Biochemistry to Bedside
Biochemistry 2018, 57, 5, 469
DOI: 10.1021/acs.biochem.7b01217
mRNA Therapies: New Hope in the Fight against Melanoma
Biochemistry 2020, 59, 17, 1650–1655
DOI: 10.1021/acs.biochem.0c00181
The Biochemistry of Survival Motor Neuron Protein Is Paving the Way to Novel Therapies for Spinal Muscle Atrophy
Biochemistry 2020, 59, 14, 1391–1397
DOI: 10.1021/acs.biochem.9b01124
Tafenoquine: A Step toward Malaria Elimination
Biochemistry 2020, 59, 8, 911–920
DOI: 10.1021/acs.biochem.9b01105
Larotrectinib in NTRK-Rearranged Solid Tumors
Biochemistry 2019, 58, 12, 1555–1557
DOI: 10.1021/acs.biochem.9b00126
Light at the End of the Amyloid Tunnel
Biochemistry 2018, 57, 41, 5921–5922
DOI: 10.1021/acs.biochem.8b00985
Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C Infection
Biochemistry 2018, 57, 5, 481–482
DOI: 10.1021/acs.biochem.7b01160
Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies
Biochemistry 2018, 57, 5, 477–478
DOI: 10.1021/acs.biochem.7b01126
Biochemical Basis of Vosevi, a New Treatment for Hepatitis C
Biochemistry 2018, 57, 5, 479–480
DOI: 10.1021/acs.biochem.7b01157
A New Step in the Treatment of Sickle Cell Disease
Biochemistry 2018, 57, 5, 470–471
DOI: 10.1021/acs.biochem.7b00785
Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis
Biochemistry 2018, 57, 5, 474–476
DOI: 10.1021/acs.biochem.7b00796
Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine
Biochemistry 2018, 57, 5, 472–473
DOI: 10.1021/acs.biochem.7b00765

Submit your own contribution to the journal.


Discover other Biochemistry collections:


Want more stories like this delivered to your inbox?

Sign up for our newsletter to receive a selection of stories related to your favorite topics.

  • This field is for validation purposes and should be left unchanged.